IL1B and metabolic dysfunction-associated steatotic liver disease: In a case-control study involving 98 participants, it was demonstrated that obesity (P < 0.01), obesity-related type 2 diabetes (T2D) (P < 0.01), and non-alcoholic fatty liver disease (NAFLD) (P < 0.05) increased the expression of various inflammasome components as well as the expression and release of IL-1β and IL-18 in AT (135).